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ORIGINAL ARTICLE VIROLOGYPre-transplant thymic function is associated with the risk of
cytomegalovirus disease after solid organ transplantationI. Gracia-Ahuﬁnger1,2, S. Ferrando-Martínez3,4,5, M. Montejo6, M. C. Muñoz-Villanueva1,2, S. Cantisán1,2, A. Rivero1,2, R. Solana1,2,
M. Leal3 and J. Torre-Cisneros1,2
1) Maimónides Institute for Research in Biomedicine of Córdoba (IMIBIC), Reina Soﬁa University Hospital, University of Cordoba, Cordoba, 2) Spanish Network for
Infectious Disease Research (REIPI RD12/0015), Instituto de Salud Carlos III, 3) Immunovirology Laboratory, Infectious Diseases Clinical Unit, Microbiology and
Preventive Medicine, Biomedicine Institute of Seville (IBIS), Virgen del Rocío University Hospital, University of Seville, Seville, 4) Molecular Immunology Laboratory,
Instituto de Investigación Sanitaria Hospital Gregorio Marañón, Madrid, 5) Networking Research Centre on Bioengineering, Biomaterials and Nanomedicine
(CIBER-BBN) and 6) Infectious Diseases Unit, Cruces University Hospital, Bilbao, SpainAbstractCytomegalovirus (CMV) disease is an important complication in solid organ transplant recipients. Thymic function in adults is associated with
speciﬁc T-cell immunity. Pre-transplant thymic function was analysed in 75 solid organ transplant patients by the use of nested PCR. The
primary outcome was the incidence of CMV disease 12 months after transplantation. Using multivariable logistic regression, we studied
whether pre-transplant thymic function is an independent risk factor for CMV disease after transplantation. Thymic function was related
to the risk of CMV disease in CMV-seropositive recipients. In these recipients, pre-transplant thymic function of <9.5 (OR 11.27, 95% CI
1.11–114.43, p 0.040) and the use of thymoglobulin (OR 8.21, 95% CI 1.09–61.84, p 0.041) were independent risk factors for CMV
disease at 12 months after transplantation. Patients with pre-transplant thymic function values of <9.5 had a higher subsequent incidence
of CMV disease (24%) than patients with values of 9.5 (3%) (log-rank test: 5.727; p 0.017). The positive and negative predictive values
of these pre-transplant thymic function cut-offs were 0.24 (95% CI 0.10–0.45) and 0.97 (95% CI 0.82–1.00), respectively. Pre-transplant
thymic function in CMV-seropositive candidates could be useful in determining the risk of post-transplant CMV disease in solid organ
transplant patients, selecting a group of low-risk candidates.
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to this workIntroductionThe risk of cytomegalovirus (CMV) disease and strategies for
CMV prevention have traditionally been deﬁned by the type ofClinical Microbiology and Infection © 2015 European Society of Corgan transplant, donor/recipient CMV serology, and the
immunosuppression used [1–4]. Currently, the indication for
preventive management is based on the recognition of these risk
factors in the pre-transplant period. In recent years, remarkable
advances have beenmade in understanding the risk factors, in the
design of prevention strategies, and in new techniques for viro-
logical and immunological monitoring. The pre-transplant sero-
logical status of candidates is used as a surrogate marker for the
presence of CMV-speciﬁc immunity [5,6]. However, there is
evidence that serology is not the best method for deﬁning the
immune status of transplant candidates. In a previous study, we
showed that the pre-transplant production of interferon (IFN)-γClin Microbiol Infect 2015; 21: 511.e1–511.e7
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2014.12.020
511.e2 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIby CMV-speciﬁc T-lymphocytes is associated with the risk of
CMV replication after transplantation. In that study, one-third of
the CMV-seropositive recipients (R+) did not produce enough
IFN-γ, and this was associated with an increased risk of CMV
replication [7]. Identifying the immune characteristics of each
individual therefore provides an opportunity to individualize
preventive management [5,8].
Determining the protective capacity of the transplant re-
cipient’s immune system would also be of crucial importan-
ce.The thymus is critical for the formation of the immune
system and T-cells during the fetal stage [9]. For years, it has
been assumed that the generation of T-lymphocytes is ﬁxed in
childhood. However, some studies have shown that the adult
thymus may reverse the process of atrophy to facilitate
improved recovery of the immune system [10,11], and adult
thymic tissue even maintains the thymopoietic capacity [12].
There is evidence of a relationship between thymic function and
speciﬁc T-cell immunity in adults. CMV-speciﬁc T-cell immunity
can predict the risk of CMV infection or disease [12–15]. We
hypothesized that insufﬁcient thymic function in solid organ
transplant (SOT) candidates may increase the risk of CMV
disease after transplantation. Therefore, a higher level of pre-
transplant thymic function could mean greater control of vi-
rus replication in all patients. Also, a failure of thymic function
during the pre-transplant period could be considered to be a
major risk factor for the development of CMV replication and
disease in the post-transplant period.Materials and methodsStudy design and population
A longitudinal study of a cohort of SOT patients from two
centres of the REIPI network was carried out. Patients were
eligible if they were aged >14 years. The CMV prevention
protocol was as follows. Universal prophylaxis was used in
heart (3 months), lung (6 months) and pancreas–kidney
(6 months) transplant recipients, as well as in kidney and liver
transplant recipients (3 months) considered to be at high risk
(CMV-seropositive donor/CMV-seronegative recipient (D+/
R–), and use of induction therapy with thymoglobulin). In the
remaining patients, pre-emptive therapy was used. Monitoring
of viral load (COBAS AmpliPrep/COBAS Amplicor; Roche
Diagnostics, Branchburg, NJ, USA) was required at least weekly
during hospitalization, twice monthly during the ﬁrst 3 months,
and monthly during the ﬁrst year. Treatment was indicated for a
minimum of 2 weeks when the viral load was >1500 copies/mL.
The drugs used for both prophylaxis and pre-emptive therapy
were intravenous ganciclovir/valganciclovir at recommended
doses in each case, and doses were adjusted for renal function ifClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectneeded. Immunosuppression was indicated according to the
protocols of each centre.
The primary study endpoint was the incidence of CMV dis-
ease within 12 months after transplantation. We assessed the
value of pre-transplant thymic function for predicting the risk of
CMV disease. For the diagnosis of disease, we used the deﬁni-
tions established by the American Society of Transplantation
for use in clinical trials [16]. In brief, CMV disease was deﬁned
as evidence of CMV infection with compatible symptoms. CMV
disease was classiﬁed as tissue-invasive disease if there was
evidence of localized CMV infection in a biopsy or another
appropriate specimen, or as CMV syndrome if there was no
such evidence.
The study was approved by the ethics committee of the
aforementioned institution.
Thymic function analysis
Thymic function was determined by quantitative nested PCR
in frozen blood samples from the pre-transplant study. De-
tails of this technique have been published elsewhere [17].
Brieﬂy, the samples are ampliﬁed in triplicate in a ﬁrst con-
ventional PCR. Two primary reactions are performed for
each sample. In a PCR tube, the T-cell receptor excision
circle (sj-TREC) is ampliﬁed (δTREC) with a pair of speciﬁc
oligonucleotides. In the other PCR tube, six of the 13
possible βTRECs are ampliﬁed (six corresponding to cluster
1) in a multiplex reaction with six sense oligonucleotides that
hybridize to speciﬁc areas on each TREC, and with an anti-
sense oligonucleotide that hybridizes in the common area
shared by six TRECs. The six sense oligonucleotides also have
a random sequence on the 30 end (T3 tail), which is needed to
standardize the results. Each triplicate is ampliﬁed on a Light-
Cycler 480 II with speciﬁc FRET probes as a detection
method. A mixture of the ﬁrst two PCRs (δTREC and six
βTRECs) is diluted 1 : 10 and used for quantitative PCR. For
ampliﬁcation of βTREC, an antisense oligonucleotide that
hybridizes to the common area shared by the six TRECs and
a sense oligonucleotide that hybridizes to the T3 tail added to
the six amplicons are used. Thus, an integrated signal of the
six βTRECs is obtained with a single pair of oligonucleotides.
The δTREC/βTREC ratio can be determined in a single re-
action vial by the use of FRET probes with different wave-
lengths (Red-610 and Red-640).
Variables associated with CMV disease
We studied the potential relationship between the develop-
ment of CMV disease at 12 months after transplantation and the
following variables: age, gender, type of organ transplant,
donor/recipient serology, prevention strategy, immunosup-
pression, and pre-transplant thymic function.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 511.e1–511.e7
CMI Gracia-Ahuﬁnger et al. Pretransplant thymic function and CMV disease 511.e3Statistical analysis
The proportions were compared by use of the chi-square
statistic for contingency tables and Fisher’s exact test when
indicated. Quantitative variables were expressed as mean ±
standard deviation or median and minimum–maximum values.
Normality was checked with Shapiro–Wilk test. Mean and
median values were compared by use of Student’s t-test or the
Mann–Whitney’s U-test. Pearson correlation coefﬁcients were
also calculated. To study the risk factors for CMV disease, a
bivariate analysis was performed with simple logistic regression
followed by multivariate analysis with logistic regression. After
methodical selection of the variables included in the multivar-
iate model, variables found to be signiﬁcant in the bivariate
analysis and others considered to be clinically important were
included in the multiple logistic regression model. The cut-offs
of pre-transplant thymic function associated with the best
sensitivity and speciﬁcity were analysed by means of receiver
operating characteristic curve analysis. Given that values of
<9.5 were associated with the risk of mortality in a previous
study, we started from the assumption that this value could be a
valid cut-off point to categorize thymic function [18]. The
incidence of CMV disease according to the categorized pre-
transplant thymic function was calculated by the use of
Kaplan–Meier curves. Differences were assessed with the log-
rank test. The performance of pre-transplant thymic function in
detecting the risk of CMV disease was assessed by calculating
the sensitivity, speciﬁcity, positive predictive value (PPV), and
negative predictive value (NPV). All analyses were performed
with PASW Statistics 18 software (IBM Corporation, Armonk,
NY, USA). p-Values were considered to be statistically signiﬁ-
cant at p < 0.05, and hypothesis tests were two-sided.ResultsBaseline characteristics of the patients included in the
study
A total of 75 patients were enrolled in the study. The median
age was 47 years (range 15–74 years). Sixty-one patients (81%)
were male. Forty-seven patients (63%) received a kidney
transplant, six patients (8%) a heart transplant, 11 patients
(15%) a lung transplant, and 11 patients (15%) a pancreas–
kidney transplant. The majority were R+ (57 patients, 76%), and
14 patients (19%) were D+/R– . Forty-four patients (59%)
received universal prophylaxis, and 31 patients (41%) received
pre-emptive therapy. Regarding baseline immunosuppression,
83% (62 patients) received tacrolimus and 17% (11 patients)
cyclosporine. Nine patients (12%) received induction with
thymoglobulin, and ﬁve (7%) with basiliximab. Six patients (8%)Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inreceived mammalian target of rapamycin inhibitors. Ten pa-
tients (13%) received steroid boluses, owing to rejection.
Thymic function
The median pre-transplant thymic function was 13.1 (range
0.004–665.52). An inverse correlation between thymic func-
tion and age was observed (r = –0.260, p 0.025). The median
thymic function was lower in candidates aged >50 years (7.8,
range 0.2–117.8) than in candidates aged 15–50 years (17.3,
range 0.004–665.52), with p 0.013. No differences were found
in pre-transplant thymic function associated with CMV repli-
cation. A moderate positive correlation was observed between
pre-transplant thymic function and day of onset of CMV repli-
cation (r = 0.441, p 0.017). This correlation was stronger in
younger patients (r = 0.680, p 0.007). No correlation was
observed between thymic function and peak viral load in pa-
tients with CMV replication.
Thymic function was lower in seronegative recipients than in
seropositive patients (27.78 ± 27.57 vs. 42.48 ± 120.84, p
0.398). We also found no differences in pre-transplant thymic
function of R+ patients associated with CMV replication. In
R+ patients, there was a positive correlation between pre-
transplant thymic function and the day of ﬁrst detection of
CMV replication (r = 0.527, p 0.017).
According to the receiver operating characteristic curve
analysis, thymic function values of <9.5 have 86% sensitivity and
62% speciﬁcity for predicting subsequent CMV disease.
Risk factors for CMV disease
During the ﬁrst year after transplantation, 29 patients had CMV
replication (16 patients received universal prophylaxis and 13
patients pre-emptive therapy) at a median of 98 days (range
28–344 days). Twelve of 29 patients had CMV disease (seven
viral syndrome, four colitis, and one pneumonitis) at a median
of 129.5 days (range 28–285 days). Eight of 12 patients received
universal prophylaxis and four patients received pre-emptive
therapy. No episode of CMV disease was observed while pa-
tients were on prophylaxis.
Table 1 shows the variables studied as potential risk factors
for CMV disease in the 75 patients analysed. In the ﬁnal
multivariate model, variables independently associated with the
risk of CMV disease were serology D+/R– (OR 6.67, 95% CI
1.49–29.73, p < 0.013) and induction of immunosuppression
with thymoglobulin (OR 6.00, 95% CI 1.07–33.53, p < 0.041)
(Table 2). Although pre-transplant thymic function levels were
signiﬁcantly lower in patients who developed CMV disease
(12.01 ± 12.43 vs. 44.08 ± 115.11, p 0.035), neither pre-
transplant thymic function as a continuous variable or pre-
transplant thymic function as an sj-TREC/βTREC ratio of <9.5fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 511.e1–511.e7
TABLE 2. Multivariate analysis of risk factors for cytomegalovirus disease in solid organ transplant recipients (n [ 75)
Risk factor
Initial model Final model
Coefﬁcient Adjusted OR (95% CI) p Coefﬁcient Adjusted OR (95% CI) p
Age (per year) 0.02 1.02 (0.97–1.07) 0.500 — — —
Non-renal transplant –0.35 0.71 (0.09–5.35) 0.735 — — —
Serology D+/R– 2.82 16.84 (2.33–121.56) 0.005 1.90 6.67 (1.49–29.73) 0.013
Prevention with pre-emptive therapy 0.71 2.04 (0.29–14.44) 0.477 — — —
Use of thymoglobulin 2.11 8.29 (0.79–86.63) 0.077 1.79 6.00 (1.07–33.53) 0.041
Thymic function <9.5 1.39 4.03 (0.81–20.01) 0.088 — — —
TABLE 1. Bivariate analysis of risk factors for cytomegalovirus disease in solid organ transplant recipients (n [ 75)
Variable
Cytomegalovirus disease
Disease (n [ 12) No disease (n [ 63) OR (95% CI) p
Age (years), mean ± SD 49 ± 17 46 ± 13 1.01 (0.97–1.06) 0.550
Age >50 years (n = 34) 6 (50) 28 (44) 1.25 (0.36–4.30) 0.723
Male gender (n = 61) 10 (83) 51 (81) 1.17 (0.23–6.08) 0.846
Serology D+/R– (n = 14) 5 (42) 9 (14) 4.29 (1.11–16.49) 0.034
Non-renal transplant (n = 30) 4 (33) 26 (41) 0.71 (0.19–2.61) 0.608
Prevention with pre-emptive therapy (n = 31) 4 (33) 27 (43) 0.67 (0.18–2.45) 0.541
Use of thymoglobulin (n = 9) 3 (25) 6 (9) 3.17 (0.67–14.98) 0.146
Use of basiliximab (n = 5) 2 (17) 3 (5) 2.00 (0.77–5.20) 0.155
Use of tacrolimus (n = 60) 10 (83) 53 (84) 1.00 (0.19–5.28) 0.999
Use of mycophenolate (n = 73) 11 (92) 62 (98) 0.18 (0.01–3.05) 0.234
Use of mTOR inhibitors (n = 6) 1 (8) 5 (8) 1.05 (0.11–9.92) 0.963
Use of bolus steroids (n = 10) 2 (17) 8 (13) 1.37 (0.25–7.45) 0.712
Thymic function <9.5 (n = 30) 7 (58) 23 (36) 2.44 (0.69–8.56) 0.165
Data are expressed as no. (%), unless stated otherwise.
mTOR, mammalian target of rapamycin; SD, standard deviation.
511.e4 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIbehaved as a risk factor for CMV disease in the ﬁnal multivariate
model (Table 2).
During the ﬁrst year after transplantation, 20 (35.1%) R+
patients had CMV replication and seven (12.3%) had CMV
disease at a median of 95.5 days (range 28–344 days) and 127
days (range 28–285 days), respectively. Table 3 shows the
bivariate analysis of the variables studied as potential risk
factors for CMV disease in the 57R + patients. Six of seven
(86%) of the R+ patients with CMV disease had a pre-
transplant thymic function of <9.5 (vs. 38% in those without
disease, p 0.041). In R+ patients with induction withTABLE 3. Bivariate analysis of risk factors for cytomegalovirus dise
Variable
Cytomegalovirus disease
Disease (n [ 7)
Age (years), mean ± SD 53 ± 16
Age >50 years (n = 30) 4 (57)
Male gender (n = 47) 5 (71)
Non-renal transplant (n = 20) 3 (43)
Prevention with pre-emptive therapy (n = 29) 3 (43)
Use of thymoglobulin (n = 8) 3 (43)
Use of basiliximab (n = 4) 1 (14)
Use of tacrolimus (n = 47) 6 (86)
Use of mycophenolate (n = 55) 6 (86)
Use of mTOR inhibitors (n = 5) 1 (14)
Use of bolus steroids (n = 8) 2 (29)
Thymic function <9.5 (n = 25) 6 (86)
Data are expressed as no. (%), unless stated otherwise.
mTOR, mammalian target of rapamycin; SD, standard deviation.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectthymoglobulin, CMV disease was also more frequent (43% vs.
10%, p 0.033). In the ﬁnal multivariate model (Table 4), pre-
transplant thymic function of <9.5 (OR 11.27, 95% CI
1.11–114.43, p 0.040) and the use of thymoglobulin (OR 8.21,
95% CI 1.09–61.84, p 0.041) were independent risk factors
for CMV disease. The area under the curve of this model was
0.82 (0.68–0.95).
Predictive value of thymic function
When the incidence of CMV disease was analysed according to
the results of thymic function in R+ patients, those patients withase in seropositive solid organ recipients (n [ 57)
No disease (n [ 50) OR (95% CI) p
49 ± 11 1.03 (0.96–1.10) 0.460
26 (52) 1.23 (0.25–6.07) 0.799
42 (84) 0.48 (0.08–2.90) 0.421
17 (34) 1.46 (0.29–7.26) 0.647
26 (52) 0.69 (0.14–3.42) 0.652
5 (10) 6.75 (1.16–39.20) 0.033
3 (6) 1.62 (0.48–5.41) 0.436
41 (85) 1.02 (0.11–9.85) 0.983
49 (98) 0.12 (0.01–2.22) 0.156
4 (8) 1.92 (0.18–20.11) 0.588
6 (12) 2.93 (0.46–18.63) 0.254
19 (38) 9.79 (1.09–87.70) 0.041
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 511.e1–511.e7
TABLE 4. Multivariate analysis of risk factors for cytomegalovirus disease in seropositive solid organ recipients (n [ 57)
Variable
Initial model Final model
Coefﬁcient Adjusted OR (95% CI) p Coefﬁcient Adjusted OR (95% CI) p
Age (per year) 0.03 1.03 (0.92–1.15) 0.610 — — —
Non-renal transplant 3.17 23.69 (0.85–664.12) 0.063 — — —
Prevention with pre-emptive therapy 2.71 14.98 (0.81–276.40) 0.069 — — —
Use of thymoglobulin 5.09 162.07 (3.89–6748.40) 0.007 2.11 8.21 (1.09–61.84) 0.041
Thymic function <9.5 2.87 17.58 (0.93–333.77) 0.056 2.42 11.27 (1.11–114.43) 0.040
CMI Gracia-Ahuﬁnger et al. Pretransplant thymic function and CMV disease 511.e5levels of <9.5 had a higher subsequent incidence of CMV dis-
ease (24%) than patients with levels of 9.5 (3%) (log-rank test:
5.727; p 0.017; Fig. 1.). The performance of the thymic function
assay with the cut-off of 9.5 for predicting CMV disease was as
follows: sensitivity 0.86 (95% CI 0.42–0.99), speciﬁcity 0.62
(95% CI 0.47–0.75), PPV 0.24 (95% CI 0.10–0.45), and NPV
0.97 (95% CI 0.82–1.00)..
.
.
.
.
.
.
.
.
.
.
FIG. 1. Kaplan–Meier curves of the incidence of cytomegalovirus (CMV) dise
Thymic function values: <9.5 vs. 9.5 (log-rank test: 5.727; p 0.017).
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InDiscussionThe main conclusion of this study is that thymic function failure,
deﬁned as a pre-transplant sj-TREC/βTREC ratio of <9.5 (thymic
function deﬁcit), is a risk factor for CMV disease in CMV-
seropositive SOT recipients. It is well known that innate and
adaptive immunity play an important role in the control of CMVase according to the results of the pretransplant thymic function assay.
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 511.e1–511.e7
511.e6 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMI[19,20]. Some factors, such as Toll-like receptor (TLR)2 and
TLR4 polymorphisms, have been associated with the risk of CMV
disease [21]. The individual characteristics of the natural killer
response also seem to be important [22–24]. Adaptive immunity
plays an essential role, so that hypogammaglobulinaemia is a risk
factor in heart and lung transplantation [25,26]. T-cell responses,
particularly those of CD4+ and CD8+ T-cells, are critically
important components of CMV immune control. Immune
monitoring of CMV-speciﬁc T-cell responses can predict in-
dividuals at increased risk for CMV disease post-transplant, and
may be useful in guiding prophylaxis and pre-emptive therapies.
The majority of assays rely on the detection of IFN-γ after
stimulation of whole blood or peripheral blood mononuclear
cells withCMV-speciﬁc antigens or peptides. In addition to IFN-γ,
other markers, including interleukin-2, tumour necrosis factor-
α, CD107, and CD154, have been used to correlate CMV-
speciﬁc T-cell responses with the risk of CMV.
There is evidence that a candidate’s pre-transplant immu-
nological status may be useful for deﬁning the risk of CMV after
transplantation. Although this has been classically done by
identifying serological status, today we can determine the TLR
polymorphisms [21] or the functionality of the CMV-speciﬁc T-
cell response by measuring the production of INF-γ [7].
In the ﬁeld of ageing, thymic function in adults and the elderly
plays an active role in the maintenance of the peripheral virgin
lymphocyte subpopulation [13]. Moreover, failure in the adult
thymus is associated not only with a smaller proportion of naive
lymphocytes, but alsowith the accumulation of cellular defects that
potentially decrease lymphocyte function [15]. Also, levels of
thymic function are independently associated with crude mortality
in healthy elderly individuals [18]. In our study, we found that the
lack of thymic function in CMV-seropositive candidates is associ-
ated with an increased risk of CMV disease. Our observation
possibly reﬂects the importance of thymic function in adults to
maintain CMV-speciﬁc immunity in individuals in whom it is
assumed to have memory. It seems reasonable to assume that
patients with poor thymic function become high-risk patients, as
we found that six of the seven seropositive recipients with CMV
disease had a thymic function of <9.5. This value has been associ-
ated with increased mortality in the healthy elderly [18], and sug-
gests that ‘thymic failure’may be indicative of an impaired immune
system that has deteriorated toomuch to controlCMVreplication.
Another risk factor for the development of CMV disease is
the type of prevention therapy (patients receiving pre-emptive
therapy as compared with universal prophylaxis). Different
studies [6,8] have established that both strategies are effective
in preventing CMV disease during the time in which they are
carried out (3–6 months). In D+/R– patients, universal pro-
phylaxis favours the development of late disease after discon-
tinuation of prophylaxis. Obviously, the strategies are not equalClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectin terms of asymptomatic replication. Pre-emptive therapy does
not prevent asymptomatic replication, as it is the marker used
to start treatment. Therefore, the strategies are not equivalent
in terms of avoiding asymptomatic CMV replication, and that is
why we have not performed the analysis in terms of CMV
replication but in terms of CMV disease. In our opinion, the
posibility that prevention strategy is acting as a confusing vari-
able is controlled by including it in the multivariate analysis.
Thus, independent variables included in the multivariate analysis
are controlled by the type of prevention.
In a previous study, we found that one-third of CMV-
seropositive candidates have deﬁcient CMV-speciﬁc T-cell func-
tion, as measured by the production of INF-γ, and this deﬁcit is
associated with the increased risk of replication after trans-
plantation [7]. It is necessary to study whether the functional
deﬁcit in CMV-speciﬁc T-cell immunity could be related to
impaired thymic function in SOT candidates. In this study, how-
ever, thymic function was not associated with the risk of CMV
replication. A correlation was not found between the intensity of
replication and pre-transplant thymic function. This may be
because 59% of the entire cohort and 49% of CMV-seropositive
recipients were given universal prophylaxis, thereby inhibiting
viral replication. However, lower pre-transplant thymic function
was found to be associated with earlier onset of CMV replication.
Owing to its high NPV, inclusion of the study of thymic
function in assessing pre-transplant CMV-seropositive candi-
dates could aid in identifying a subgroup of low-risk patients
suitable for individualized CMV prevention. Nevertheless, it is
premature to base any recommendation for changing CMV
prevention strategies on the basis of our data. The thymic
function value seems to be a supplementary tool for the pre-
diction of patients at high risk of developing CMV disease.
However, the PPV is very low as reported (0.24), and it is
difﬁcult to validate the use of 9.5 as a universal cut-off in
R + SOT recipients. Additional interventional studies based on
this and other markers of risk are necessary to determine
whether patients could beneﬁt from not performing prevention
in low-risk organs or of performing pre-emptive therapy rather
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